PhaseBio Pharmaceuticals Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. PhaseBio Pharmaceuticals recent Real Value cannot be determined due to lack of data. The prevailing price of PhaseBio Pharmaceuticals is $0.0. Our model determines the value of PhaseBio Pharmaceuticals from analyzing the company fundamentals such as Shares Owned By Insiders of 6.72 %, return on equity of -30.91, and Current Valuation of 160.62 K as well as examining its technical indicators and probability of bankruptcy.
PhaseBio Pharmaceuticals Total Value Analysis
PhaseBio Pharmaceuticals is at this time forecasted to have valuation of 160.62 K with market capitalization of 3.5 M, debt of 1.36 M, and cash on hands of 7.8 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the PhaseBio Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
160.62 K | 3.5 M | 1.36 M | 7.8 M |
PhaseBio Pharmaceuticals Investor Information
About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.38. PhaseBio Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to PhaseBio Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, PhaseBio Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.PhaseBio Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PhaseBio Pharmaceuticals has an asset utilization ratio of 0.0179 percent. This implies that the Company is making $1.79E-4 for each dollar of assets. An increasing asset utilization means that PhaseBio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.PhaseBio Pharmaceuticals Ownership Allocation
PhaseBio Pharmaceuticals owns a total of 49.86 Million outstanding shares. Over half of PhaseBio Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.PhaseBio Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 10.83 K. Net Loss for the year was (131.07 K) with loss before overhead, payroll, taxes, and interest of (91.28 M).PhaseBio Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as PhaseBio Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.4 M | |
| Retained Earnings | -391.8 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in PhaseBio Stock
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |